HBL - Hadasit Bio-Holdings Ltd

Equities

HDST-M

IL0010954050

Biotechnology & Medical Research

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 15:24:59 25/06/2024 BST			5-day change	1st Jan Change
38 ^ILa	0.00%		0.00%	-43.28%

06-20	Pakistan stocks hit record high on budget, IMF optimism	RE
03-12	HBL - Hadasit Bio-Holdings Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI

HBL Hadasit Bio : The company has become a "shell company", the sector classification of the company will be changed as of May 7, 2024

May 05, 2024 at 02:39 pm

PUBT - PHS

Attachments

Original Link
Permalink

Disclaimer

HBL Hadasit Bio Holdings Ltd. published this content on 05 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 May 2024 13:38:10 UTC.

Latest news about HBL - Hadasit Bio-Holdings Ltd

Pakistan stocks hit record high on budget, IMF optimism	06-20	RE
HBL - Hadasit Bio-Holdings Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	03-12	CI
CEO of Pakistan's largest bank picked to lead country out of economic crisis	03-11	RE
Pakistan's HBL CEO Aurangzeb resigns from bank, letter to bourse shows	03-11	RE
Chief of Pakistan's largest bank likely to be included in new finance team, sources say	03-05	RE
HBL - Hadasit Bio-Holdings Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	17/08/23	CI
Hadasit Bio-Holdings Ltd Reports Earnings Results for the Half Year Ended June 30, 2021	19/08/21	CI
Hadasit Bio-Holdings, Ltd. Auditor Raises 'Going Concern' Doubt	29/03/17	CI
Cell Cure Neurosciences Ltd. announced that it expects to receive $1.6 million in funding from Hadasit Bio-Holdings, Ltd. and other investors.	20/11/16	CI
Cell Cure Neurosciences Ltd. announced that it expects to receive $3.5 million in funding from Hadasit Bio-Holdings, Ltd. and other investors	31/07/16	CI

Chart HBL - Hadasit Bio-Holdings Ltd

Duration

Period

More charts

Company Profile

HBL Hadasit Bio Holdings Ltd (Hadasit) is an investment company, a subsidiary of Hadassah Medical Organization (HMO). The Companyâs subsidiaries enable research and development and promote intellectual property (IP) to the medical and biotechnological industries. The Company together with its strategic partners, has established a number of start-up companies, and is assigned to commercialize that IP either through granting a product license to biotechnological or pharmaceutical companies or via the creation of a subsidiary which operates in the premise of HMO. Hadasit is equipped with resources and capabilities required for composing and conducting the pre-clinical services and clinical studies, establishing start-up companies, offering product licensing and providing international consulting services. The Companyâs framework serves to address investment in early-stage biotechnological star-ups, by distributing both risk and success amongst a number of companies.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
HBL - HADASIT BIO-HOLDINGS LTD	-43.28%	1.13M
MODERNA, INC.	+38.36%	52.5B
LONZA GROUP AG	+36.73%	39.31B
IQVIA HOLDINGS INC.	-8.63%	39.01B
ALNYLAM PHARMACEUTICALS, INC.	+25.46%	28.2B
CELLTRION, INC.	-11.17%	26.57B
ICON PUBLIC LIMITED COMPANY	+11.44%	26.2B
UNITED THERAPEUTICS CORPORATION	+45.09%	14.15B
MEDPACE HOLDINGS, INC.	+32.93%	12.62B
BIO-TECHNE CORPORATION	-5.30%	11.74B

Other Biotechnology & Medical Research